Enochian Biosciences Inc.changed its name toRenovaro Biosciences Inc. and reported a deal to merge part of the company with Gedi Cube Intl Ltd. in an effort to move on from recent controversies. “Renovaro, Latin for ‘renewal,’ represents our company’s mission,” said Mark Dybul, CEO of the company.
In a study reported in the online edition of Science on Aug. 10, 2023, a group of synthetic biologists from the University of California (UC) San Diego and clinicians from Australia have engineered synthetic bacteria to detect specific DNA sequences in the genomes of colorectal cancer (CRC) cells and organoids. This living cell sensor capable of detecting cancer in the colons of mice has the potential to steer the way to new biosensors capable of identifying various infections, cancers and other diseases.
TYK Medicines Inc. has described transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.
Genprex Inc. announced that the FDA has granted orphan drug designation to the company's lead drug candidate, Reqorsa immunogene therapy (quaratusugene ozeplasmid, GPX-001), for the treatment of small cell lung cancer (SCLC). Reqorsa contains a plasmid that expresses the tumor suppressor gene TUSC2, the expression of which is reduced or not present in SCLC.
In a study reported in the online edition of Science on Aug. 10, 2023, a group of synthetic biologists from the University of California (UC) San Diego and clinicians from Australia have engineered synthetic bacteria to detect specific DNA sequences in the genomes of colorectal cancer (CRC) cells and organoids. This living cell sensor capable of detecting cancer in the colons of mice has the potential to steer the way to new biosensors capable of identifying various infections, cancers and other diseases.
A complete response letter (CRL) from the U.S. FDA for GC-4419 (avasopasem) is causing Galera Therapeutics Inc. to dramatically change course to survive, with the company laying off about 70% of its workforce. That layoff, which will reach across several company departments, is designed to extend the cash runway into the second quarter of 2024. The adjustment comes after Galera expanded its commercial leadership in May to prep for a potential launch of avasopasem before the end of 2023.
The accelerated clearance won by Johnson & Johnson (J&J) from the U.S. FDA for Talvey (talquetamab-tgvs) for relapsed or refractory multiple myeloma (r/r MM) in adults brings to the market the bispecific antibody that takes aim at G protein-coupled receptor class C group 5 member D, a target of interest to other developers as well.
RSS
